Next Article in Journal / Special Issue
Measles–Rubella Microarray Patches Phase III Clinical Trial Framework: Proposal and Considerations
Previous Article in Journal
SARS-CoV-2-Neutralizing Antibodies
Previous Article in Special Issue
The Health and Economic Benefits of United States Investments in Measles and Rubella Control and Elimination
 
 
Article

Article Versions Notes

Vaccines 2024, 12(11), 1257; https://doi.org/10.3390/vaccines12111257
Action Date Notes Link
article xml file uploaded 6 November 2024 02:09 CET Original file -
article xml uploaded. 6 November 2024 02:09 CET Update -
article pdf uploaded. 6 November 2024 02:09 CET Version of Record https://www.mdpi.com/2076-393X/12/11/1257/pdf-vor
article supplementary file uploaded. 6 November 2024 02:09 CET - https://www.mdpi.com/2076-393X/12/11/1257#supplementary
article html file updated 6 November 2024 02:11 CET Original file -
article xml file uploaded 7 November 2024 03:03 CET Update -
article xml uploaded. 7 November 2024 03:03 CET Update https://www.mdpi.com/2076-393X/12/11/1257/xml
article pdf uploaded. 7 November 2024 03:03 CET Updated version of record https://www.mdpi.com/2076-393X/12/11/1257/pdf
article html file updated 7 November 2024 03:04 CET Update https://www.mdpi.com/2076-393X/12/11/1257/html
Back to TopTop